Cubist Systematic Strategies LLC increased its stake in shares of ABIOMED, Inc. (NASDAQ:ABMD) by 49.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,345 shares of the medical equipment provider’s stock after purchasing an additional 1,763 shares during the period. Cubist Systematic Strategies LLC’s holdings in ABIOMED were worth $901,000 as of its most recent SEC filing.
Several other institutional investors also recently modified their holdings of the stock. Janney Montgomery Scott LLC purchased a new stake in shares of ABIOMED during the 2nd quarter valued at $284,000. Schwab Charles Investment Management Inc. boosted its position in ABIOMED by 6.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 120,219 shares of the medical equipment provider’s stock worth $17,228,000 after purchasing an additional 6,935 shares during the period. First Trust Advisors LP boosted its position in ABIOMED by 7.7% during the 2nd quarter. First Trust Advisors LP now owns 80,459 shares of the medical equipment provider’s stock worth $11,530,000 after purchasing an additional 5,777 shares during the period. Dupont Capital Management Corp boosted its position in ABIOMED by 57.3% during the 2nd quarter. Dupont Capital Management Corp now owns 6,618 shares of the medical equipment provider’s stock worth $948,000 after purchasing an additional 2,412 shares during the period. Finally, SG Americas Securities LLC boosted its position in ABIOMED by 16.2% during the 2nd quarter. SG Americas Securities LLC now owns 18,168 shares of the medical equipment provider’s stock worth $2,603,000 after purchasing an additional 2,534 shares during the period. Hedge funds and other institutional investors own 90.45% of the company’s stock.
In other ABIOMED news, VP Michael G. Howley sold 10,000 shares of the stock in a transaction that occurred on Monday, October 30th. The shares were sold at an average price of $178.64, for a total value of $1,786,400.00. Following the completion of the sale, the vice president now owns 56,757 shares in the company, valued at approximately $10,139,070.48. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dorothy E. Puhy sold 6,364 shares of the stock in a transaction that occurred on Monday, October 30th. The stock was sold at an average price of $179.08, for a total transaction of $1,139,665.12. Following the completion of the sale, the director now owns 39,532 shares of the company’s stock, valued at approximately $7,079,390.56. The disclosure for this sale can be found here. 7.00% of the stock is owned by corporate insiders.
A number of analysts recently weighed in on ABMD shares. Zacks Investment Research cut shares of ABIOMED from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. BTIG Research lowered shares of ABIOMED from a “buy” rating to a “neutral” rating in a report on Monday, October 16th. Piper Jaffray Companies boosted their price objective on shares of ABIOMED to $200.00 and gave the stock an “overweight” rating in a report on Thursday, October 26th. Leerink Swann restated an “outperform” rating and issued a $200.00 target price (up previously from $180.00) on shares of ABIOMED in a research note on Thursday, October 12th. Finally, Jefferies Group upped their target price on shares of ABIOMED from $208.00 to $220.00 and gave the company a “buy” rating in a research note on Thursday, December 21st. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $199.67.
ABIOMED, Inc. (ABMD) traded up $4.96 during midday trading on Friday, reaching $215.11. 283,326 shares of the company’s stock traded hands, compared to its average volume of 202,602. The company has a current ratio of 5.84, a quick ratio of 5.20 and a debt-to-equity ratio of 0.02. The company has a market cap of $9,292.02, a PE ratio of 105.97, a price-to-earnings-growth ratio of 2.77 and a beta of 0.15. ABIOMED, Inc. has a 1 year low of $103.53 and a 1 year high of $216.15.
ABIOMED (NASDAQ:ABMD) last posted its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.54 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.16. ABIOMED had a net margin of 18.27% and a return on equity of 13.89%. The business had revenue of $132.80 million during the quarter, compared to analysts’ expectations of $131.18 million. During the same period last year, the firm posted $0.20 earnings per share. The business’s revenue was up 28.9% on a year-over-year basis. equities research analysts anticipate that ABIOMED, Inc. will post 2.41 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Cubist Systematic Strategies LLC Has $901,000 Stake in ABIOMED, Inc. (ABMD)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this story on another domain, it was illegally stolen and reposted in violation of United States and international trademark and copyright legislation. The original version of this story can be accessed at https://www.dispatchtribunal.com/2018/01/13/cubist-systematic-strategies-llc-grows-holdings-in-abiomed-inc-abmd.html.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED and related companies with MarketBeat.com's FREE daily email newsletter.